Eos Biotechnology

Eos Biotechnology, Inc. "is a privately held biotechnology company based in South San Francisco. Using its proprietary, leading-edge genomic technologies and best-of-breed research tools, Eos has developed an integrated approach for identifying novel disease targets and developing highly specific antibodies against them.  Eos' first therapeutic antibody IND, for Eos200-4, was filed last year, and the antibody is directed against a cellular target molecule identified by Eos' proprietary genomics platform.  Eos has a pipeline of over 20 other therapeutic targets and, in many cases, cognate antibodies rapidly moving towards the clinic."

Merged into Protein Design Labs in 2003.

Contact

 * Web: n/a